retosiban
Sign in to saveAlso known as GSK-221,149-A
Retosiban also known as GSK-221,149-A is an oral drug which acts as an oxytocin receptor antagonist. It is being developed by GlaxoSmithKline for the treatment of preterm labour. Retosiban has high affinity for the oxytocin receptor (Ki = 0.65 nM) and has greater than 1400-fold selectivity over the related vasopressin receptors
Wikidata facts
- Mass
- 494.25292018799996
Show 4 more facts
- Commons category
- Retosiban
- isomeric SMILES
- CC[C@H](C)[C@@H]1C(=O)N[C@@H](C(=O)N1[C@H](c2coc(n2)C)C(=O)N3CCOCC3)C4Cc5ccccc5C4
- chemical formula
- C₂₇H₃₄N₄O₅
- canonical SMILES
- CCC(C)C1C(=O)NC(C2Cc3ccccc3C2)C(=O)N1C(C(=O)N1CCOCC1)c1coc(C)n1
via Wikidata · CC0
~6 min read
Article
7 sectionsContents
- Mechanism of action
- Pharmacology
- Pharmacokinetics
- Physical and chemical properties
- Synthesis
- See also
- References
Retosiban also known as GSK-221,149-A is an oral drug which acts as an oxytocin receptor antagonist. It is being developed by GlaxoSmithKline for the treatment of preterm labour. Retosiban has high affinity for the oxytocin receptor (Ki = 0.65 nM) and has greater than 1400-fold selectivity over the related vasopressin receptors
==Mechanism of action== Retosiban is a competitive oxytocin receptor antagonist which blocks the oxytocin-mediated contraction of the uterine smooth muscle in the female uterus that occurs during the initiation of preterm labour. This has been used to prevent preterm labour and premature birth.